Kent Kresa takes over as MannKind’s Chairman of the Board

MannKind Corporation has announced the resignation of Alfred Mann as Executive Chairman and the appointment of Kent Kresa as Chairman of the Board, effective immediately. Mann will continue as a non-executive advisor, the company said.

Kresa is Chairman Emeritus of Northrop Grumman Corporation and has served on the boards of numerous companies, universities, and non-profits, including General Motors and Caltech.

MannKind CEO Matthew Pfeffer commented, “Al founded this company in order to bring his unique flair for medical innovation to the biopharmaceutical space. We are awed by his many accomplishments during a legendary career and are proud to continue Al’s decades-long pursuit of addressing the unmet needs of patients with diabetes and other serious illnesses.”

Kresa added, “Al is a true visionary and has created a great company with an impressive lead product and powerful technology to help patients with serious diseases. We have much to do to make his dreams a reality, but we have the people, technology and know-how to make that happen.”

The company is gearing up to market Afrezza inhaled insulin once it regains the rights from Sanofi and for development of other inhaled drugs in partnership with Receptor LIfe Sciences.

Read the MannKind press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan